This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 18 No. 2, August 2007
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fimbres, A.
Right arrow Articles by Barton, L. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fimbres, A.
Right arrow Articles by Barton, L. L.

AAP Grand Rounds 18:16-17 (2007)
© 2007 American Academy of Pediatrics

RESIDENTS/INFECTIOUS DISEASES

How Effective Is the Quadrivalent HPV Vaccine at Preventing High-grade Cervical Lesions?

Source: The FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927; doi:10.1056/NEJMoa061741[Abstract/Free Full Text]

The first 20% of the full text of this article appears below.

Human papillomaviruses (HPV) cause virtually all cervical cancers, with HPV types 16 and 18 responsible for the majority of cases.1 HPV types 6 and 11 cause the majority of anogenital warts.2 A quadrivalent HPV vaccine against HPV types 6/11/16/18 was approved by the FDA in June 2006. Researchers from 13 countries conducted a study to assess the efficacy of HPV vaccine in preventing cervical intraepithelial neoplasia (CIN) grade 2 or 3, adenocarcinoma in situ, and cervical cancer caused by HPV-16 or HPV-18.

Over a one-year period, 12,167 women between the ages of 15 and 26 were enrolled in this double-blind, placebo-controlled, randomized trial. Women were eligible for participation in the study if they were not pregnant, had no history of an abnormal Papanicolaou smear, and reported having had no more than four sex partners. Participants were randomly assigned to receive vaccine or placebo at day 1, month 2, and month 6. . . . [Full Text of this Article]

Angela Fimbres, MD, MPH1 and Leslie L. Barton, MD, FAAP2
1 Pediatric Infectious Diseases, Northwestern University, Children’s Memorial Hospital, Chicago, IL
2 Pediatrics, University of Arizona School of Medicine, Tucson, AZ